GlucoTrack, Inc. (NASDAQ:GCTK) Short Interest Update

by · The Cerbat Gem

GlucoTrack, Inc. (NASDAQ:GCTK – Get Free Report) was the target of a large decline in short interest in August. As of August 31st, there was short interest totaling 24,951 shares, a decline of 85.0% from the August 15th total of 165,864 shares. Based on an average daily trading volume, of 207,650 shares, the short-interest ratio is presently 0.1 days. Approximately 3.8% of the shares of the stock are short sold.

Institutional Investors Weigh In On GlucoTrack

A number of institutional investors have recently made changes to their positions in the business. Ikarian Capital LLC bought a new position in shares of GlucoTrack during the 4th quarter valued at $177,000. Boothbay Fund Management LLC bought a new position in shares of GlucoTrack during the fourth quarter valued at about $52,000. Finally, Bank of America Corp DE grew its stake in shares of GlucoTrack by 102,125.0% during the second quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock valued at $25,000 after buying an additional 4,085 shares during the last quarter. Hedge funds and other institutional investors own 10.92% of the company’s stock.

GlucoTrack Price Performance

NASDAQ:GCTK traded down $0.68 during mid-day trading on Friday, reaching $2.55. The stock had a trading volume of 740,839 shares, compared to its average volume of 137,657. The firm has a 50 day moving average price of $5.40 and a two-hundred day moving average price of $9.66. The stock has a market capitalization of $1.81 million, a P/E ratio of -0.02 and a beta of 0.62. GlucoTrack has a one year low of $2.26 and a one year high of $212.10. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.46 and a current ratio of 0.46.

Analysts Set New Price Targets

Several research firms have recently weighed in on GCTK. Wall Street Zen upgraded shares of GlucoTrack from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of GlucoTrack in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Read Our Latest Stock Analysis on GlucoTrack

GlucoTrack Company Profile

(Get Free Report)

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.

See Also